Bayer Announces Addition of Nevaxar to Tarceva Failed

On July 23rd, 2012 Reuters reported that the combination of cancer drugs Tarceva and Nevaxar for liver cancer patients’ treatment was declared by Bayer as failure. Tarceva, sold by Astellas Pharma Inc and Genentech, a unit of Roche Holding, is a drug used to treat patients with unresectable cancer of the lung or of the pancreas that is either spreading locally or has metastasized. In July 2009, the US FDA announced the drug’s label information warning about three kinds of serious adverse events including gastrointestinal perforation, which can be fatal. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Tarceva severe adverse events. [http://www.attorneyone.com/tarceva-lawsuit/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Tarceva: severe adverse events

Tarceva: severe adverse events

alerted healthcare professionals about hepatic failure and hepatorenal syndrome with the use of Tarceva

San Diego, CA (PRWEB) August 27, 2012

The media spotlight is often a double-edged sword. No one knows this better than patients who suffer from Tarceva severe adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

On July 23rd, 2012 Reuters reported that the combination of cancer drugs Tarceva and Nevaxar for liver cancer patients’ treatment was declared by Bayer as failure. Tarceva, sold by Astellas Pharma Inc and Genentech, a unit of Roche Holding, is a drug used to treat patients with unresectable cancer of the lung or of the pancreas that is either spreading locally or has metastasized. According to the report, the drugs combination failed to improve overall survival rates compared with standard Nexavar treatment in a late-stage Phase III trial.

In July 2009, the US FDA announced the drug’s label information warning about three kinds of serious adverse events:

  •     gastrointestinal perforation, which can be fatal
  •     bullous, blistering and exfoliative skin conditions, possibly including Stevens-Johnson syndrome and toxic epidermal necrolysis
  •     ocular disorders, including corneal perforation or ulceration.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe complications from Tarceva, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Tarceva remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In December 2008, as the FDA published, Genentech alerted healthcare professionals about hepatic failure and hepatorenal syndrome with the use of Tarceva (erlotinib), particularly in patient with baseline hepatic impairment.

AttorneyOne.com has further information on Tarceva lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/8/prweb9802030.htm.